ClinicalTrials.gg
CompletedNCT04257032Updated Feb 23, 2024Results posted

A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

A Phase 1 interventional study of Rosuvastatin and Rosuvastatin + BI 1323495 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following oral administration.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead , and clinical laboratory tests
  2. Age of 18 to 55 years (inclusive)
  3. of 18.5 to 29.9 kg/m2 (inclusive)
  4. Signed and dated written prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation
  5. Subjects genotyped as Uridine 5'-diphospho-Glucuronosyltransferase-2B17 (UGT2B17) extensive metabolisers, i.e. carrying at least one functional allele of UGT2B17 gene (*1/*1 or *1/*2)

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance (including positive or missing faecal occult blood test in Part 2)
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts
  9. Chronic or relevant acute infections
  10. History of relevant allergy or (including allergy to the trial medications or their )
  11. Use of drugs within 30 days of planned administration of trial medication that might reasonably influence the results of the trial or compromise the subject's safety by participation in the trial (e. g. use of any drug that could reasonably inhibit aggregation or coagulation, concomitant treatment with systemic cyclosporine, ketoconazole, itraconazole and dronedarone, use of fibrates or drugs that cause /QTc interval prolongation (QTc: QT interval corrected for heart rate using the method of Fridericia (QTcF) or Bazett (QTcB))
  12. Intake of an drug in another clinical trial within 60 days of planned administration of investigational drug in the current trial, or concurrent participation in another clinical trial in which investigational drug is administered
  13. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  14. Inability to refrain from smoking on specified trial days
  15. Alcohol abuse (consumption of more than 24 g per day)
  16. Drug abuse or positive drug screening
  17. Blood donation of more than 100 mL within 30 days of planned administration of trial medication or intended blood donation during the trial
  18. Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
  19. Inability to comply with the dietary regimen of the trial site
  20. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
  21. A history of additional risk factors for Torsade de Pointes (such as heart failure, hypokalaemia, or family history of Long QT Syndrome)
  22. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because the subject is not considered able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
  23. Male subjects with women of (WOCBP) partner who are unwilling to use male (condom or sexual abstinence) from time point of administration of trial medication until 30 days thereafter. Sperm donation is not allowed from the time point of drug administration until 30 days thereafter.
  24. Active clinically relevant bleeding or subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of blood coagulation disorders, current or recent gastrointestinal ulceration, presence of malignant neoplasms, recent brain or spinal injury, recent brain/spinal/ophthalmic surgery, recent intracranial hemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms, major intraspinal or intracerebral vascular abnormalities
  25. For Part 1 only: known myopathy, personal or family history of hereditary muscular disorders, or history of muscular toxicity with statins or fibrate; Asian ancestry; hypothyroidism
  26. Subjects with any other condition that would preclude administration of rosuvastatin or dabigatran (i.e. as per SmPC), such as active liver disease including elevations of serum transaminases exceeding 2 times the , moderate or severe renal impairment ( \< 60 ml/min based on estimated (GFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula), prosthetic heart valves requiring anticoagulant treatment
  27. During COVID-19 pandemic: laboratory test indicative of an ongoing SARS-CoV-2 infection
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Reference 1 (R1)

    Drug: Rosuvastatin

  • Experimental
    Test 1 (T1)

    Drug: Rosuvastatin + BI 1323495

  • Experimental
    Reference 2 (R2)

    Drug: Dabigatran etexilate

  • Experimental
    Test 2 (T2)

    Drug: Dabigatran etexilate + BI 1323495

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of the analyte (rosuvastatin) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Rosuvastatin (Reference 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration. Rosuvastatin + BI 1323495 (Test 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration.

    Time frame: Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.

  2. Part 1: Maximum Measured Concentration of the Analyte (Rosuvastatin) in Plasma (Cmax)

    Maximum measured concentration of the analyte (rosuvastatin) in plasma (Cmax). Rosuvastatin (Reference 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration. Rosuvastatin + BI 1323495 (Test 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration.

    Time frame: Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.

  3. Part 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of the analyte (dabigatran) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) Dabigatran (Reference 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration. Dabigatran + BI 1323495 (Test 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration.

    Time frame: Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.

  4. Part 2: Maximum Measured Concentration of the Analyte (Dabigatran) in Plasma (Cmax)

    Maximum measured concentration of the analyte (dabigatran) in plasma (Cmax) Dabigatran (Reference 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration. Dabigatran + BI 1323495 (Test 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration.

    Time frame: Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.

Secondary outcomes

  1. Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of the analyte (rosuvastatin) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Rosuvastatin (Reference 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration. Rosuvastatin + BI 1323495 (Test 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration.

    Time frame: Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.

  2. Part 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of the analyte (dabigatran) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) Dabigatran (Reference 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration. Dabigatran + BI 1323495 (Test 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration.

    Time frame: Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.

07

Results

Posted Feb 23, 2024

Participant flow

An open, single-dose, randomised, two-period, two way crossover design in each trial part to evaluate the relative bioavailability of rosuvastatin (Part 1) and dabigatran (Part 2) given alone and together with BI 1323495 in healthy male subjects.

Period 1 (+ Washout Period)
Participant flow — Period 1 (+ Washout Period)
MilestonePart 1: Rosuvastatin (R1) / Rosuvastatin + BI 1323495 (T1)Part 1: Rosuvastatin + BI 1323495 (T1) / Rosuvastatin (R1)Part 2: Dabigatran (R2) / Dabigatran + BI 1323495 (T2)Part 2: Dabigatran + BI 1323495 (T2) / Dabigatran (R2)
Started7777
Completed7777
Not completed0000
Period 2
Participant flow — Period 2
MilestonePart 1: Rosuvastatin (R1) / Rosuvastatin + BI 1323495 (T1)Part 1: Rosuvastatin + BI 1323495 (T1) / Rosuvastatin (R1)Part 2: Dabigatran (R2) / Dabigatran + BI 1323495 (T2)Part 2: Dabigatran + BI 1323495 (T2) / Dabigatran (R2)
Started7777
Completed7777
Not completed0000

Outcome measures

PrimaryPart 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of the analyte (rosuvastatin) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Rosuvastatin (Reference 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration. Rosuvastatin + BI 1323495 (Test 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration.

Time frame:
Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.
Reported as:
Geometric least squares mean · Hours * nanogramm / milliliter
Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Hours * nanogramm / milliliterRosuvastatin (Part 1, Reference 1)Rosuvastatin + BI 1323495 (Part 1, Test 1)
Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)23.92 ± NA25.20 ± NA
Statistical analysis
  • Rosuvastatin (Part 1, Reference 1) vs Rosuvastatin + BI 1323495 (Part 1, Test 1) · ANOVA · Ratio of geometric means (t/r) %: 105.37 · 90% CI 97.94 to 113.35Intra-individual coefficient of variation (gCV %) = 9.9
PrimaryPart 1: Maximum Measured Concentration of the Analyte (Rosuvastatin) in Plasma (Cmax)

Maximum measured concentration of the analyte (rosuvastatin) in plasma (Cmax). Rosuvastatin (Reference 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration. Rosuvastatin + BI 1323495 (Test 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration.

Time frame:
Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.
Reported as:
Geometric least squares mean · Nanogramm / milliliter
Part 1: Maximum Measured Concentration of the Analyte (Rosuvastatin) in Plasma (Cmax)
Nanogramm / milliliterRosuvastatin (Part 1, Reference 1)Rosuvastatin + BI 1323495 (Part 1, Test 1)
Part 1: Maximum Measured Concentration of the Analyte (Rosuvastatin) in Plasma (Cmax)2.20 ± NA2.52 ± NA
Statistical analysis
  • Rosuvastatin (Part 1, Reference 1) vs Rosuvastatin + BI 1323495 (Part 1, Test 1) · ANOVA · Ratio of geometric means (t/r) %: 114.50 · 90% CI 104.22 to 125.81Intra-individual coefficient of variation (gCV %) = 14.0
PrimaryPart 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of the analyte (dabigatran) in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) Dabigatran (Reference 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration. Dabigatran + BI 1323495 (Test 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration.

Time frame:
Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.
Reported as:
Geometric least squares mean · Hours * nanogramm / milliliter
Part 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Hours * nanogramm / milliliterDabigatran (Part 2, Reference 2)Dabigatran + BI 1323495 (Part 2, Test 2)
Part 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)666.24 ± NA720.76 ± NA
Statistical analysis
  • Dabigatran (Part 2, Reference 2) vs Dabigatran + BI 1323495 (Part 2, Test 2) · ANOVA · Ratio of geometric means (t/r) %: 108.18 · 90% CI 100.26 to 116.73Intra-individual coefficient of variation (gCV %) = 11.3
PrimaryPart 2: Maximum Measured Concentration of the Analyte (Dabigatran) in Plasma (Cmax)

Maximum measured concentration of the analyte (dabigatran) in plasma (Cmax) Dabigatran (Reference 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration. Dabigatran + BI 1323495 (Test 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration.

Time frame:
Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.
Reported as:
Geometric least squares mean · Nanogramm / milliliter
Part 2: Maximum Measured Concentration of the Analyte (Dabigatran) in Plasma (Cmax)
Nanogramm / milliliterDabigatran (Part 2, Reference 2)Dabigatran + BI 1323495 (Part 2, Test 2)
Part 2: Maximum Measured Concentration of the Analyte (Dabigatran) in Plasma (Cmax)80.01 ± NA87.12 ± NA
Statistical analysis
  • Dabigatran (Part 2, Reference 2) vs Dabigatran + BI 1323495 (Part 2, Test 2) · ANOVA · Ratio of geometric means (t/r) %: 108.89 · 90% CI 99.84 to 118.76Intra-individual coefficient of variation (gCV %) = 12.9
SecondaryPart 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of the analyte (rosuvastatin) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). Rosuvastatin (Reference 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration. Rosuvastatin + BI 1323495 (Test 1) was measured within 3 hours (h) before drug administration and 1h, 2h, 3h, 3h 30 minutes (min) 4h, 4h 30min, 5h, 5h 30min, 6h, 7h, 8h, 10h, 12h, 24h, 34h, 47h, 71h and 95h after drug administration.

Time frame:
Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.
Reported as:
Geometric least squares mean · Hours * nanogramm / milliliter
Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Hours * nanogramm / milliliterRosuvastatin (Part 1, Reference 1)Rosuvastatin + BI 1323495 (Part 1, Test 1)
Part 1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)21.50 ± NA22.47 ± NA
Statistical analysis
  • Rosuvastatin (Part 1, Reference 1) vs Rosuvastatin + BI 1323495 (Part 1, Test 1) · ANOVA · Ratio of geometric means (t/r) %: 104.52 · 90% CI 97.34 to 112.23Intra-individual coefficient of variation (gCV %) = 10.6
SecondaryPart 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of the analyte (dabigatran) in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) Dabigatran (Reference 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration. Dabigatran + BI 1323495 (Test 2) was measured within 3 hours (h) before drug administration and 30 minutes (min), 1h, 1h 30 min, 2h, 2h 30 min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 47h and 71h after drug administration.

Time frame:
Measured within 3 hours (h) before and up to 95h after drug administration. Detailed time frame is in description section.
Reported as:
Geometric least squares mean · Hours * nanogramm / milliliter
Part 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Hours * nanogramm / milliliterDabigatran (Part 2, Reference 2)Dabigatran + BI 1323495 (Part 2, Test 2)
Part 2: Area Under the Concentration-time Curve of the Analyte (Dabigatran) in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)647.05 ± NA701.55 ± NA
Statistical analysis
  • Dabigatran (Part 2, Reference 2) vs Dabigatran + BI 1323495 (Part 2, Test 2) · ANOVA · Ratio of geometric means (t/r) %: 108.42 · 90% CI 100.37 to 117.12Intra-individual coefficient of variation (gCV %) = 11.5

Adverse events

Collected over From the time of administration of test or reference treatment until administration time of next study drug dose or until 0:00 h on day 7 after time of administration, whatever occurs first, up to 7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin (Part 1, Reference 1)0/14 (0%)0/14 (0%)4/14 (28.6%)
Rosuvastatin + BI 1323495 (Part 1, Test 1)0/14 (0%)0/14 (0%)5/14 (35.7%)
Dabigatran (Part 2, Reference 2)0/14 (0%)0/14 (0%)0/14 (0%)
Dabigatran + BI 1323495 (Part 2, Test 2)0/14 (0%)0/14 (0%)1/14 (7.1%)
Most frequent other events
Most frequent other events
EventRosuvastatin (Part 1, Reference 1)Rosuvastatin + BI 1323495 (Part 1, Test 1)Dabigatran (Part 2, Reference 2)Dabigatran + BI 1323495 (Part 2, Test 2)
HeadacheNervous system disorders3/144/140/140/14
FatigueGeneral disorders1/140/140/140/14
NasopharyngitisInfections and infestations0/141/140/140/14
Ligament sprainInjury, poisoning and procedural complications0/140/140/141/14
Neck painMusculoskeletal and connective tissue disorders0/141/140/140/14
Disturbance in attentionNervous system disorders1/140/140/140/14

Baseline characteristics

Treated set (TS): The TS included all subjects who were randomised and treated with at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)Part 1: Rosuvastatin (R1) / Rosuvastatin + BI 1323495 (T1)Part 1: Rosuvastatin + BI 1323495 (T1) / Rosuvastatin (R1)Part 2: Dabigatran (R2) / Dabigatran + BI 1323495 (T2)Part 2: Dabigatran + BI 1323495 (T2) / Dabigatran (R2)Total
Mean40.4 ± 10.344.3 ± 7.736.6 ± 10.335.7 ± 7.439.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Rosuvastatin (R1) / Rosuvastatin + BI 1323495 (T1)Part 1: Rosuvastatin + BI 1323495 (T1) / Rosuvastatin (R1)Part 2: Dabigatran (R2) / Dabigatran + BI 1323495 (T2)Part 2: Dabigatran + BI 1323495 (T2) / Dabigatran (R2)Total
Female00000
Male777728
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Rosuvastatin (R1) / Rosuvastatin + BI 1323495 (T1)Part 1: Rosuvastatin + BI 1323495 (T1) / Rosuvastatin (R1)Part 2: Dabigatran (R2) / Dabigatran + BI 1323495 (T2)Part 2: Dabigatran + BI 1323495 (T2) / Dabigatran (R2)Total
Hispanic or Latino00000
Not Hispanic or Latino777728
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Rosuvastatin (R1) / Rosuvastatin + BI 1323495 (T1)Part 1: Rosuvastatin + BI 1323495 (T1) / Rosuvastatin (R1)Part 2: Dabigatran (R2) / Dabigatran + BI 1323495 (T2)Part 2: Dabigatran + BI 1323495 (T2) / Dabigatran (R2)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White777728
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: https://www.mystudywindow.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Sep 2020, 7 months.

Results were first posted in Feb 2024, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
Feb 5, 2020
StartActual
Feb 13, 2020
Primary completionActual
Sep 23, 2020
CompletionActual
Sep 23, 2020
Results first posted
Feb 23, 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04257032
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Feb 13, 2020
Primary completion
Sep 23, 2020
Completion
Sep 23, 2020
Results posted
Feb 23, 2024
Last update
Feb 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · BI 1323495 · Dabigatran

Start the discussion